PROSIEBENSAT1 MED. (OTCMKTS:PBSFF) has received a consensus rating of “Hold” from the six research firms that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, four have given a hold recommendation and one has given a buy recommendation to the company.

Several equities research analysts recently issued reports on PBSFF shares. BNP Paribas downgraded PROSIEBENSAT1 MED. from an “outperform” rating to a “neutral” rating in a research note on Friday, July 7th. Citigroup Inc. reissued a “neutral” rating on shares of PROSIEBENSAT1 MED. in a research note on Tuesday, May 9th. Finally, DZ Bank AG reaffirmed a “sell” rating on shares of PROSIEBENSAT1 MED. in a research report on Wednesday, April 19th.

ILLEGAL ACTIVITY WARNING: This piece of content was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at

Shares of PROSIEBENSAT1 MED. (OTCMKTS:PBSFF) opened at 38.60 on Friday. The stock has a market cap of $8.83 billion and a PE ratio of 18.86. PROSIEBENSAT1 MED. has a 12-month low of $33.70 and a 12-month high of $45.81. The firm has a 50-day moving average price of $40.34 and a 200 day moving average price of $41.67.

PROSIEBENSAT1 MED. Company Profile

Analyst Recommendations for PROSIEBENSAT1 MED. (OTCMKTS:PBSFF)

Receive News & Stock Ratings for PROSIEBENSAT1 MED. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PROSIEBENSAT1 MED. and related stocks with our FREE daily email newsletter.